Table 2.

Serial plasma blood draws show stable treprostinil levels with long-lasting infusion sites

Subject/sample	Day	Plasma concentration (ng/mL)	Normalized concentration (D7)	Treprostinil dose (ng/kg/min)
X-01 04-01-11	7	17.80	1.00	119
X-01 04-26-11	30	18.80	1.06	119
X-01 05-06-11	7	16.50	1.00	119
X-01 05-26-11	30	15.60	0.95	119
X-01 06-23-11	60	14.50	0.88	119
X-01 07-25-11	90	16.60	1.01	119
X-01 08-01-11	7	20.70	1.00	119
X-01 08-25-11	30	16.50	0.80	119
X-01 09-21-11	60	21.10	1.02	140
Y-10 04-05-11	7	13.60	1.00	73
Y-10 04-25-11	30	7.08	0.52	73
Y-10 05-26-11	60	12.40	0.91	73
Y-10 08-11-11	7	14.80	1.00	73
Y-10 09-06-11	30	13.00	0.88	73
Y-10 10-03-11	60	7.18	0.49	73
Y-10 03-07-11	7	13.90	1.00	73
Y-10 03-28-11	30	12.20	0.88	73
Z-07 04-14-11	7	16.30	1.00	170
Z-07 05-09-11	30	14.10	0.87	170
Z-07 06-13-11	7	20.30	1.00	170
Z-07 07-08-11	30	15.40	0.76	170
W-06 04-05-11	7	9.00	1.00	54
W-06 04-28-11	30	7.14	0.79	54
W-06 05-26-11	60	8.84	0.98	54
W-06 08-11-11	7	8.64	1.00	54
W-06 08-31-11	30	6.65	0.77	54
W-06 10-12-11	60	12.20	1.41	54
W-06 10-27-11	90	9.40	1.09	54
V-24 08-05-11	7	6.09	1.00	47
V-24 08-26-11	30	7.78	1.28	47
V-24 09-22-11	60	5.82	0.96	47
V-24 10-07-11	7	6.51	1.00	47
V-24 10-28-11	30	5.44	0.84	47
U-21 04-06-11	7	11.30	1.00	78
U-21 05-03-11	30	11.80	1.04	62
U-21 06-03-11	60	9.96	0.88	62

^NoteFor complete details, see legend to Figure 5. Underlining denotes 2 cases in which the treprostinil dose changed during the plasma collection period. In the first case (X-01), the dose increased at day 60, and we excluded that sample from the reported analysis (and the graphs). It is included in this table for completeness. In the second case (U-21), the dose was decreased, but the value at day 30 was still higher than that at day 7 (D7). We therefore included that sample because the variability observed was similar to that for the overall population of samples.